• In this study, we will investigate the effect of the study compound on how the body processes different approved medications. The study compound is approved in the United States and the European Union for the treatment of desmoid tumors. Desmoid tumors are rare tumors that develop in connective tissue and are classified as benign to malignant. They are usually found in the abdomen, chest, neck, arms or legs.
• In addition to the study compound, you will also be administered various approved medications.
• The study compound will be given twice daily for 17 days. The study compound will be given as tablets taken by mouth with water. The approved medications will be given two times in total. The approved medications will be given as a drink and tablets that will be taken by mouth with water.

You may also experience other, yet unknown, side effects. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects. This information will also be discussed with you at the start of the medical screening. You can then ask questions to the screening physician or nurse. Once everything is clear to you, you can decide to give written consent to participate in the trial. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.

• You are a healthy male.
• You are at least 18 and at most 55 years old.
• Your weight is at least 50 kg and your Body Mass Index (BMI) is at least 18.0 and at most 32.0 kg/m2. 
• You did not smoke and did not use nicotine-containing products for 2 months prior to the medical screening.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 30 days prior to the first compound administration in this clinical trial (counting from the last dosing).
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.
• You can only participate if you meet one of the following conditions:
  • You are using a condom in combination with an additional contraception method used by your female partner (for example the pill or an intrauterine device);
  • You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
  • You are not sexually active according to your lifestyle;
  • You are only sexually active with a partner of the same sex.

The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 22 days (21 nights). After your departure there will be a phone follow-up.

Note: You must be available for all dates to be able to participate in this clinical trial.